JP2025500438A5 - - Google Patents
Info
- Publication number
- JP2025500438A5 JP2025500438A5 JP2024538028A JP2024538028A JP2025500438A5 JP 2025500438 A5 JP2025500438 A5 JP 2025500438A5 JP 2024538028 A JP2024538028 A JP 2024538028A JP 2024538028 A JP2024538028 A JP 2024538028A JP 2025500438 A5 JP2025500438 A5 JP 2025500438A5
- Authority
- JP
- Japan
- Prior art keywords
- modified oligonucleotide
- modified
- nucleic acid
- nucleoside
- nucleosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163292829P | 2021-12-22 | 2021-12-22 | |
| US63/292,829 | 2021-12-22 | ||
| PCT/US2022/082164 WO2023122681A2 (en) | 2021-12-22 | 2022-12-21 | Compounds and methods for reducing pcdh19 expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025500438A JP2025500438A (ja) | 2025-01-09 |
| JP2025500438A5 true JP2025500438A5 (enExample) | 2026-01-06 |
Family
ID=86903772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538028A Pending JP2025500438A (ja) | 2021-12-22 | 2022-12-21 | Ｐｃｄｈ１９発現を低減するための化合物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250340874A1 (enExample) |
| EP (1) | EP4453216A4 (enExample) |
| JP (1) | JP2025500438A (enExample) |
| WO (1) | WO2023122681A2 (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5624892B2 (ja) * | 2008-01-04 | 2014-11-12 | セントラル アデレード ローカル ヘルス ネットワーク インコーポレイテッド | Ｅｆｍｒ（女性に限られた癲癇及び精神遅滞）の診断方法及び治療方法 |
| US9567581B2 (en) * | 2012-08-07 | 2017-02-14 | The General Hospital Corporation | Selective reactivation of genes on the inactive X chromosome |
-
2022
- 2022-12-21 US US18/722,875 patent/US20250340874A1/en active Pending
- 2022-12-21 EP EP22912708.9A patent/EP4453216A4/en active Pending
- 2022-12-21 WO PCT/US2022/082164 patent/WO2023122681A2/en not_active Ceased
- 2022-12-21 JP JP2024538028A patent/JP2025500438A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7315594B2 (ja) | Ｌｒｒｋ２発現を低減するための化合物及び方法 | |
| TWI809004B (zh) | 用於降低snca表現之化合物及方法 | |
| JP2022515193A5 (enExample) | ||
| EP3664816A1 (en) | Oligonucleotide compositions and methods thereof | |
| JP2022518929A5 (enExample) | ||
| JP2023536472A5 (enExample) | ||
| JP7446443B2 (ja) | Ｓｍｎ２を調節するための化合物及び方法 | |
| JP2023536994A5 (enExample) | ||
| CN119790152A (zh) | 使用unc13a基因转录本的调节剂治疗神经系统疾病 | |
| JP2022527105A5 (enExample) | ||
| JP2024504377A5 (enExample) | ||
| KR20240049349A (ko) | Scn1a 발현을 조절하기 위한 화합물 및 방법 | |
| CN119522282A (zh) | 具有经修饰的主链化学的剪接转换器反义寡核苷酸 | |
| TW202111123A (zh) | 用於減少fus 表現之化合物及方法 | |
| JP2025500438A5 (enExample) | ||
| JP2024522147A5 (enExample) | ||
| JP2023543215A5 (enExample) | ||
| JP2023530072A5 (enExample) | ||
| JP2023528755A5 (enExample) | ||
| AU2021284360A1 (en) | Treatment of neurological diseases using modulators of gene transcripts | |
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| JP2026506010A (ja) | Ａｐｐ発現を低減するための化合物及び方法 | |
| TW202435898A (zh) | 用於調節杭丁頓蛋白表現之對偶基因選擇性化合物及方法 | |
| JP2025532127A (ja) | Ｍｅｃｐ２発現を低減する化合物及び方法 | |
| JP2023532518A (ja) | Ｐｌｐ１を調節するための化合物及び方法 |